HC Wainwright Has Negative Estimate for uniQure Q1 Earnings

uniQure N.V. (NASDAQ:QURE) – Equities researchers at HC Wainwright reduced their Q1 2026 EPS estimates for uniQure in a research note issued on Tuesday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will earn ($0.79) per share for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.43) EPS, FY2027 earnings at ($3.95) EPS, FY2028 earnings at ($3.19) EPS, FY2029 earnings at $0.21 EPS and FY2030 earnings at $4.19 EPS.

A number of other brokerages have also commented on QURE. Barclays started coverage on uniQure in a report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price target on the stock. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Leerink Partners reiterated an “outperform” rating and set a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Finally, Wolfe Research began coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

uniQure Price Performance

Shares of NASDAQ QURE opened at $16.94 on Thursday. The company has a market capitalization of $1.06 billion, a PE ratio of -4.91 and a beta of 0.73. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock’s 50 day moving average price is $21.53 and its 200-day moving average price is $29.49. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new stake in shares of uniQure during the second quarter valued at about $29,217,000. State Street Corp boosted its position in shares of uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its position in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC grew its stake in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new stake in uniQure during the 4th quarter worth approximately $33,062,000. Institutional investors own 78.83% of the company’s stock.

Insiders Place Their Bets

In other uniQure news, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. The trade was a 44.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider owned 138,483 shares in the company, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,399 shares of company stock worth $1,527,645 in the last three months. Insiders own 4.79% of the company’s stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.